Evaluation of Corrected QT Intervals of 74 COVID19 Patients Treated with Hydroxychloroquine in Combination with or without Azithromycin and/or Favipiravir


Abstract views: 107 / PDF downloads: 75

Authors

DOI:

https://doi.org/10.5152/eurjther.2021.21022

Keywords:

COVID-19, corrected QT, hydroxychloroquine, azithromycin, favipiravir

Abstract

Objective: We aimed to evaluate the degree of QTc prolongation and associated factors in patients with COVID-19 in association with their usage of hydroxychloroquine (HCQ) with or without the combination of azithromycin (AZ) and/or favipiravir (FAV). Methods: This single-center, retrospective study was conducted in a tertiary care university hospital. We retrospectively examined the pre- and post-treatment electrocardiogram (ECG) records of 74 patients. Results: The median age was 44 (interquartile range [IQR] 27), and 34 (45.5%) of them were women. All these 74 patients were treated with HCQ. Sixty-three of them (83.2%) were treated with AZ, and eight patients (10.8%) also were treated with plus favipiravir. All ECGs were in sinus rhythm, and arrhythmia was not developed in any patients. The median (IQR) baseline QTc of 74 patients was 400 (375- 421) milliseconds, the median (IQR) post-treatment QTc was 418 milliseconds (391-432), and the change was statistically significant (P < .001). There was no statistically significant difference in QTc prolongation between treatment groups. In the linear regression model, moderate disease activity, higher Modified Early Warning Score (MEWS) score (2), and heart rate were independent predictors. QTc prolongation of more than 60 milliseconds was observed in five patients (6.7%). Post-treatment QTc value of over 500 milliseconds was observed in three patients (4%), and the drugs were discontinued. Conclusions: This is the first study that demonstrates that MEWS score and disease severity are related to higher QTc prolongation values. HCQ, AZ, and FAV should be safely used in patients with lower MEWS score and without the severe disease, in conjunction with QTc follow-up.

Metrics

Metrics Loading ...

References

World Health Organization. Coronavirus Disease (COVID-19) Dashboard. Data last updated: 2021/02/27, 3:09 pm CET. Available at

https://covid19.who.int.

Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label

non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.

Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: Open label,

randomised controlled trial. BMJ. 2020;369:M1849.

Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med.

;382(25):2411-2418.

Wallace DJ, Tse K, Hanrahan L, Davies R, Petri MA. Hydroxychloroquine usage in US patients, their experiences of tolerability and

adherence, and implications for treatment: Survey results from 3127 patients with SLE conducted by the Lupus Foundation of

America. Lupus Sci Med. 2019;6(1):E000317.

Taylor SP, Sellers E, Taylor BT. Azithromycin for the prevention of COPD exacerbations: The good, bad, and ugly. Am J Med.

;128(12):1362.e1-1362.e26.

Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021;102:501-508. [CrossRef]

Chorin E, Wadhwani L, Magnani S, et al. QT interval prolongation and torsade de pointes in patients with COVID-19 treated with

hydroxychloroquine/azithromycin. Heart Rhythm. 2020;17(9):1425-1433.

Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol.

;5(9):1036-1041. Erratum in: JAMA Cardiol. 2020;5(9):1071.

Chinello P, Petrosillo N, Pittalis S, et al. QTc interval prolongation during favipiravir therapy in an ebolavirus-infected patient. PLoS

Negl Trop Dis. 2017;11(12):E0006034.

WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. 2020. Available at https://www.who.int/news-room/detail/04-07-2020-who-discontinueshydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-forcovid-19.

Lin C. Why do Asian countries use hydroxychloroquine for Covid19 despite Western rejection? ISPSW strategy series: Focus on

defense and international security. Available at https://www.ispsw.com/wp-content/uploads/2020/08/711_Lin.pdf.

Republic of Turkey Ministry of Health Directorate General of Public Health. COVID-19 (SARS-CoV-2 Infection) Guide (in Turkish). 2020.

Available at https://hsgm.saglik.gov.tr/depo/birimler/goc_sagligi/covid19/rehber/COVID19_Rehberi20200414_eng_v4_002_14.05.2020.pdf.

World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 diseases is suspected.

Interim Guidance, March 13, 2020.

Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India.

;76(4):370-376.

The European Society for Cardiology. ESC guidance for the diagnosis and management of CV disease during the COVID-19 pandemic. Available at https://www.escardio.org/Education/COVID-19- and-Cardiology/ESC-COVID-19-Guidance.

Haeusler IL, Chan XHS, Gue´ rin PJ, et al. The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: A systematic review. BMC Med. 2018;16(1):200.

Vandael E, Vandenberk B, Vandenberghe J, Willems R, Foulon V. Risk factors for QTc-prolongation: Systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16-25.

Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol.

;5(9):1036-1041.

Crotti L, Arbelo E. COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias.

Heart Rhythm. 2020;17(9):1423-1424.

Hooks M, Bart B, Vardeny O, et al. Effects of hydroxychloroquine treatment on QT interval. Heart Rhythm. 2020;17(11):1930-1935.

Saleh M, Gabriels J, Chang D, et al. Effect of chloroquine, hydroxychloroquine, and azithromycin on the corrected QT interval in

patients with SARS-CoV-2 infection. Circ Arrhythm Electrophysiol. 2020;13(6):e008662.

Viskin S. The QT interval: Too long, too short or just right. Heart Rhythm. 2009;6(5):711-715.

Charbit B, Samain E, Merckx P, Funck-Brentano C. QT interval measurement: Evaluation of automatic QTc measurement and new

simple method to calculate and interpret corrected QT interval. Anesthesiology. 2006;104(2):255-260.

Churpek MM, Carey KA, Merced ND, Prister J, Brofman J, Edelson DP. Validation of early warning scores at two long-term acute

care hospitals. Critical Care Med. 2019;47(12):e962-e965.

Wang L, Lv Q, Zhang X, et al. The utility of MEWS for predicting the mortality in the elderly adults with COVID-19: A retrospective

cohort study with comparison to other predictive clinical scores. Peer J. 2020;8:e10018.

Downloads

Published

2021-12-27

How to Cite

Uyaroğlu, O. A., Şener, Y. Z., Özdede, M., Başaran, N. Çalık, Özışık, L., Şahin, T. K., Canpolat, U., İnkaya, A. Çağkan, Yorgun, H., Güven, G. S., & Aytemir, K. (2021). Evaluation of Corrected QT Intervals of 74 COVID19 Patients Treated with Hydroxychloroquine in Combination with or without Azithromycin and/or Favipiravir. European Journal of Therapeutics, 27(4), 311–317. https://doi.org/10.5152/eurjther.2021.21022

Issue

Section

Original Articles